Clinical trials: Active Population
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Diabetes Mellitus, Type 2
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104…
- Trial name
- NCT00226330
- Testing
- Tesaglitazar, Pioglitazone
- Where
- 171 sites in United States, Argentina and 5 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
H. Pylori Eradication Therapy
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects
- Trial name
- NCT07875933
- Volunteers
- 414 people
- Sponsor
- Onconic Therapeutics Inc.
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00611455
- Testing
- ofatumumab
- Where
- 45 sites in Argentina, Australia and 11 more
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
Primary Objective: To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in participants with active…
- Trial name
- NCT01217814
- Testing
- Sarilumab, Golimumab, methotrexate (MTX)
- Where
- 14 sites in United States, Colombia and 4 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Covid19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
The purpose of this study is to assess the immunogenicity and safety of MVC-COV1901 vaccine compared to AZD1222 in heathy adults.
- Trial name
- NCT05011526
- Testing
- MVC-COV1901, AZD1222
- Where
- 2 sites in Paraguay
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with…
- Conditions
- Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00463385
- Testing
- Pomalidomide, Prednisone
- Where
- 11 sites in United States, Austria and 3 more
- Volunteers
- 88 people
- Sponsor
- Celgene
Healthy
Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects
The purpose of this study is to determine how well tolerated and safe AZD5069 is at different dose levels in healthy male and/or females.
- Trial name
- NCT00953888
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.
- Trial name
- SCRIPT (NCT00476996)
- Testing
- Leflunomide, Methotrexate, Ocrelizumab
- Where
- 266 sites in United States, Argentina and 23 more
- Volunteers
- 836 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen…
- Trial name
- NCT01285310
- Testing
- Apremilast 30 mg, Apremilast 20 mg
- Where
- 50 sites in United States, Czechia and 2 more
- Volunteers
- 237 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis
This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in combination with methotrexate（MTX）in patients with active rheumatoid arthritis (RA).
- Trial name
- NCT00779220
- Testing
- methotrexate, ocrelizumabu 50mg, ocrelizumabu 200mg
- Where
- 7 sites in Japan
- Volunteers
- 152 people
- Sponsor
- Chugai Pharmaceutical
Seasonal Allergic Rhinitis
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen.
- Trial name
- SAR (NCT01484119)
- Testing
- ACT-129968, Cetirizine
- Where
- 7 sites in United States
- Volunteers
- 630 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Asthma
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma
- Trial name
- NCT01444430
- Testing
- Symbicort pMDI, budesonide pMDI
- Where
- 340 sites in United States, Argentina and 24 more
- Volunteers
- 12,460 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease Requiring Chronic Dialysis
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients.
- Trial name
- NCT01464190
- Testing
- PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate
- Where
- 15 sites in United States, Austria and 13 more
- Volunteers
- 659 people
- Sponsor
- Vifor Pharma
Schizophrenia
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial titration dose (2 mg) of immediate-release…
- Trial name
- NCT00791232
- Testing
- extended-release (ER) OROS paliperidone
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease. 60% of participants will receive AADvac1 and 40% of participants will receive placebo.
- Trial name
- ADAMANT (NCT02579252)
- Testing
- AADvac1
- Where
- 42 sites in Austria, Czechia and 6 more
- Volunteers
- 208 people
- Sponsor
- Axon Neuroscience SE
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Growth Hormone Deficiency, Endocrine System Diseases
Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
This study is conducted in China only. The purpose is to demonstrate the efficacy and safety of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hGH)…
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormones, Pituitary Diseases
- Trial name
- NCT04326374
- Testing
- TransCon hGH, daily hGH
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Visen Pharmaceuticals (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.